Julie Gerberding

Julie Gerberding  link LinkedIn (Civil servant)
File:Julie Gerberding.jpg
Born	22 August 1955
Nationality	US
Alma mater	Case Western Reserve University
Approved Merck vaccine Gardasil as CDC Director, salary $172,000. Then made around $25 million from stock sales when working for Merck.

Dr Julie Gerberding served as the director of the U.S. Centers for Disease Control and Prevention (CDC) for then to be rewarded with a position as executive vice president for strategic communications, global public policy & population health and the chief patient officer at Merck.

Gerberding became a nationally-recognized figure during the 2001 anthrax attacks in the United States. As the Acting Deputy Director of National Center for Infectious Diseases, Gerberding was a prominent spokeswoman for the CDC during daily briefings regarding the attacks and aftermath.

AIDS research

During her medical residency at San Francisco General Hospital, Gerberding treated some of the first hospitalized AIDS patients. She completed several studies on the risks of HIV to healthcare workers, created guidelines to prevent their infections, and established a treatment and research unit focused on HIV/AIDS cases among the urban poor.

Revolving Door

Merck’s Gardasil vaccine was approved and mandated by the CDC when Gerberding was the director of the CDC. She went from about $172,000 in salary to around $25 million in compensation from stock sales at Merck and CERN.

In late 2009, Gerberding became president of Big Pharma corporation Merck's vaccines division. According to form 4 SEC filings, between 2015 and 2020, Gerberding sold $23,968,010 in Merck stock. Since July of 2016, she was on the board of directors at the Cerner Corporation, a health care technology corporation.[ On July 17, 2020 she sold 36,285 units of CERN stock worth $2,902,800.